Searched for
CIPLA STOCK UPGRADE
Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...- Cipla shares rise over 2% as Kotak forecasts better days ahead, upgrades rating to ‘buy’Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a targe...
- InCred cuts Nifty50 blended index target to 25,327, upgrades pharma to overweightInCred Equities cut Nifty50 target to 25,327, expecting a correction phase. The brokerage upgraded its stance on pharma stocks like Cipla, ...
- Buy IT stocks on dips; not big on pharma but like specific stocks: Chakri LokapriyaChakri Lokapriya highlights a selective approach toward pharma, favoring Cipla and Piramal for potential gains due to specific catalysts li...
- Maruti Suzuki, Axis Bank among 8 stocks that earned upgrades in last 1 month. Check revised target price
- Cipla slumps nearly 8% after USFDA warning letter for manufacturing lapsesAfter an inspection at the Pithampur plant, the USFDA issued a warning letter stating that the company's methods, facilities, or controls f...
- High Hopes! 5 Nifty50 stocks see over 4% EPS upgrades post Q2 resultsEPS is an important financial measure, which indicates the profitability of a company.
- Earnings season held up well; positive on Cipla and Sun Pharma: Mayuresh Joshi"The BFSI space has held up well. Midcap IT has produced another quarter of stupendous earnings and management commentaries are pointing ou...
- Cipla surges 10% with rise in price targetsThe average price target of the 28 analysts, whose ratings and price targets that have been compiled by Bloomberg, is ₹1,161. The stock clo...
- Cipla shares jump 9% after Q1 profit soars 45% YoY to Rs 996 crore. Should you buy, sell or hold?In morning session, the scrip was trading 8.5% higher at Rs 1.160 on BSE. Meanwhile, in the last one year, it has surged 19%.
- Hot Stocks: Brokerages on Cipla, Axis Bank, Dr Reddy’s, Tech Mahindra and ColgateJefferies upgraded Cipla to buy with a target price of Rs 1210. The US performance leads to the beat in Q1 results. The management commenta...
- Most brokerages bullish on Cipla; cite US, local market growth potentialMost brokerages maintained a bullish view on Cipla citing the pharmaceutical major's healthy pipeline of product launches in the United Sta...
- Buy Cipla, target price Rs 1058: ICICI SecuritiesCipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 73066.96 Crore) operating in Pharmaceuticals s...
- CLSA upgrades Cipla to 'Buy' from 'Outperform'; raises target priceCLSA raised the target price of Cipla to Rs 655 from Rs 525 post Q1.
- Analysts bet on Cipla as acquisitions expected to boost company's growthAcquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.
- Nomura neutral on Cipla, target Rs 689Cipla has acquired a portfolio of largely plain vanilla oral solids where its capabilities are already well-established, and hence the acqu...
- Brokerages upgrade Cipla after strong Q1 resultsBrokerages have raised their EPS estimates and target price on the stock on the back of rupee depreciation and Medpro acquisition.
- Pharma stocks rally after SC's Novartis verdict; analysts positive on DRL, Cipla, NatcoPharma stocks surged 2-5 per cent after the Supreme Court dismissed Novartis AG's plea for getting its blood cancer drug patented in India.
- Broker's call on Tata Motors, Cipla and GSK ConsumersMorgan Stanley upgraded Tata Motors to ‘Overweight’ on hopes of a cyclical recovery in profitability of Indian auto industry.
- Dealing Room: Cipla, Ambuja Cements, Educomp, Bharat ForgeET Now spoke to dealers on institutional and high net worth investors’ activity in the dealing room.
Load More
